Is there any scientific evidence linking angiotensin-converting enzyme (ACE-I) or angiotensin
II receptor blockers (ARBs) to the risk of COVID-19 contracting or severity?
Hello DR Vishwanath: You can find a response in the following link:
https://www.jwatch.org/na51345/2020/04/09/ace-inhibitors-and-arbs-during-covid-19-pandemic
I hope this helps. Regards--
https://www.jwatch.org/na51345/2020/04/09/ace-inhibitors-and-arbs-during-covid-19-pandemic
ACE2 does help in the entry of SARS-CoV-2 into human cells. And previous animal studies show that ACE inhibitors and ARBs upregulates ACE2 expression. This effect could increase risk for or severity of COVID-19. Meanwhile, some researchers hypothesize that ACE inhibitors and ARBs could benefit patients with COVID-19 through various mechanisms. E.g ACE2 converts angiotensin 2 to angiotensin 1–7, that has beneficial anti inflammatory properties, by upregulating ACE2 either ACE inhibitors or ARBs, could enhance this process.
ACE Inhibitors and ARBs During the COVID-19 Pandemic Allan S. Brett et al.
- Badges
- Science topic
- Similar topics
- Biological Science
- Biochemistry
- Enzymology
- Enzymes